| Literature DB >> 32140399 |
Yiwen Zhang1, Xinyan Lv2, Jiameng Qu2, Xin Zhang1, Mingyang Zhang1, Hao Gao1, Qian Zhang1, Ran Liu1, Huarong Xu1, Qing Li1, Kaishun Bi1.
Abstract
Schisandra chinensis, a widely used Chinese herbal medicine, was considered as central nervous system (CNS) drug for years. Both ethanol extracts (EES) and water extracts (WES) of it were applied clinically. Unfortunately, the difference of their efficacy and even effective material foundation of S. chinensis remains obscure. In this study, to explore the active constituents of S. chinensis, we compared pharmacodynamics and chemical profiles in vitro/in vivo of EES/WES for the first time using multiple chemical analysis, pharmacological and data processing approaches. It was proved that there was no significant difference in the anti-depressive effects between WES and EES. However, the contents of most components in vitro and in plasma were higher in EES than those in WES, which was unconvincing for their similar efficacy. Therefore, we further explored components of S. chinensis targeted onto brain and the results showed that 5 lignans were identified with definite absorptivity respectively both in EES and WES caused by the limitation of blood-brain barrier. Moreover, bioinformatic analysis predicted their anti-depressive action. Above all, the systematic strategy screened 5 brain-targeted effective substances of S. chinensis and it was suggested that exploring the components into nidi would promote the studies on herbs effective material basis.Entities:
Keywords: Chemical profiles; Components into nidi; Effective material basis; Ethanol extracts; Pharmacodynamics; Schisandra chinensis; Traditional Chinese medicine; Water extracts
Year: 2019 PMID: 32140399 PMCID: PMC7049611 DOI: 10.1016/j.apsb.2019.10.008
Source DB: PubMed Journal: Acta Pharm Sin B ISSN: 2211-3835 Impact factor: 11.413
Figure 1The research strategy for finding the material basis for efficacy of Schisandra chinensis by comparing the chemical profiles and pharmacodynamics of EES and WES.
Figure 2(A) The immobility time in FST of groups. (B) The travel paths in the locomotor activity test. (C) The latency time to feed in NSF test. (D) The level of corticosterone in plasma samples. Values shown are means ± SD, n=6; #P < 0.01 compared with control group; *P < 0.05, **P < 0.01 compared with model group.
The concentrations of 5-HT, DA, NE in samples WES and EES.
| Analyte | Control group (ng/mg) | CUMS group (ng/mg) | WES (ng/mg) | EES (ng/mg) | Fluoxetine group (ng/mg) |
|---|---|---|---|---|---|
| 5-HT | 19.9±4.94 | 4.34±1.89## | 8.04±2.14* | 15.20±3.77** | 13.9±2.26** |
| DA | 5.49±2.29 | 2.40±1.22# | 3.54±1.28 | 6.60±2.04* | 5.51±3.13 |
| NE | 6.93±1.08 | 2.41±0.97# | 5.30±1.60* | 7.82±1.16** | 5.50±1.38* |
For statistical significance **P < 0.01, *P < 0.05 compared with CUMS group, ##P < 0.01, #P < 0.05, compared with control group.
Figure 3Effects of EES and WES on inflammation markers. Values shown are means ± SD; #P < 0.01 compared with control group; *P < 0.05, **P < 0.01 compared with CUMS.
The components in WES and EES in vitro/in vivo.
| Peak No. | Identification | Error ▵ (ppm) | Retention time (min) | [M+H]+/[M+Na]+ ( | Fragment ions ( |
|---|---|---|---|---|---|
| 1 | Citric/isocitric acid | 2.2 | 2.02 | 193.0278 [M+H]+ | 216.1779, 148.1526, 129.0188, 111.0081, 87.0087 |
| 2 | 1,5-Dimethyl citrate | 0.7 | 5.05 | 221.0583 [M+H]+ | 185.0400, 157.0493, 129.0185, 111.0082, 87.0088 |
| 3 | Schindilactone D | 2 | 15.05 | 561.2341 [M+H]+ | 501.2136, 423.1792, 401.1073, 320.6077, 242.2852 |
| 4 | Schisanwilsonin B | 0.0 | 15.06 | 501.2046 [M+H]+ | 483.1986, 455.2089, 437.1956, 365.1784, 317.1752 |
| 5 | PRXFPPAVWQDTHT-UHFFFAOYSA-N | 0.7 | 16.82 | 419.1992 [M+H]+ | 426.1799, 401.1980, 395.1494, 369.1716, 337.1453 |
| 6 | Schisanwilsonin D | 0.6 | 18.39 | 503.2203 [M+H]+ | 525.2078, 425.1567, 354.1457, 339.1205, 266.0913 |
| 7 | Schisandrol A | 0.4 | 24.49 | 433.2148 [M+H]+ | 400.1885, 384.1930, 346.1413, 331.1184, 300.0996 |
| 8 | Schisantherin E | 0.8 | 27.35 | 539.2203 [M+H]+ | 561.2099, 439.1719, 417.1922, 357.1347, 342.1487 |
| 9 | Gomisin D | 0.9 | 27.79 | 531.2152 [M+H]+ | 485.2177, 467.2040, 401.1594, 326.1139, 353.1371 |
| 10 | Rubrisandrin A | 1.5 | 29.14 | 389.1886 [M+H]+ | 389.1977, 357.1684, 325.1451, 288.0977, 227.0713 |
| 11 | Gomisin J | 1.5 | 29.44 | 389.1886 [M+H]+ | 357.1708, 326.1457, 319.1162, 287.0908, 255.0646 |
| 12 | Gomisin O | 0.8 | 30.02 | 417.1835 [M+H]+ | 399.1813, 369.1630, 337.1419, 316.0960, 277.1228 |
| 13 | Epigomisin O | 0.8 | 30.33 | 417.1835 [M+H]+ | 399.1813, 369.1630, 337.1419, 316.0960, 277.1228 |
| 14 | Wilsonilignan C | 0.8 | 31.12 | 417.1835 [M+H]+ | 399.1813, 368.1681, 355.1648, 314.1040, 299.0895 |
| 15 | Schisphenlignan A | 1.7 | 31.59 | 523.189 [M+H]+ | 423.1425, 383.1530, 352.0834, 341.1024, 326.1151 |
| 16 | Schisandrol B | 0.8 | 31.90 | 417.1835 [M+H]+ | 399.1804, 369.1700, 330.1100, 229.0921, 263.1079 |
| 17 | Angeloygomisin H/Tigloylgomisin H | 1.0 | 40.69 | 501.2412 [M+H]+ | 483.2374, 451.2159, 401.1963, 370.1779, 337.1443 |
| 18 | Benzoylgomisin H | −0.4 | 43.94 | 523.2254 [M+H]+ | 545.2141, 515.1654, 503.1874, 455.1392, 355.1554 |
| 19 | Benzoylgomisin Q | −0.6 | 44.56 | 553.2359 [M+H]+ | 453.1896, 387.1882, 356.1620, 343.1177, 301.1071 |
| 20 | Angeloylgomisin Q/Tigloylgomisin Q | −0.5 | 46.07 | 531.2516 [M+H]+ | 553.2389, 453.1875, 431.2050, 371.1477, 341.1371 |
| 21 | Gomisin C | 0.2 | 50.60 | 537.2046 [M+H]+ | 559.1936, 437.7814, 415.1754, 341,1380, 299.0911 |
| 22 | Benzoylgomisin P | 0.2 | 50.62 | 537.2046 [M+H]+ | 437.1569, 415.1754, 371.1482, 340.1303, 310.1189 |
| 23 | Schisanhenol | 0.0 | 62.02 | 403.2042 [M+H]+ | 371.1845, 340.1667, 301.1063, 271.0948, 270,0885 |
| 24 | Schisantherin D | −2.9 | 64.26 | 521.1733 [M+H]+ | 421.1237, 399.1439, 355.1172, 325.1084, 295.0084 |
| 25 | gomisinE | −0.5 | 69.17 | 515.2203 [M+H]+ | 469.2176, 438.1765, 423.1801, 385.1647, 355.1543 |
| 26 | Schisantherin B | −0.5 | 69.20 | 515.2203 [M+H]+ | 469.2207, 421.1801, 385,1635, 355,1531, 302.0772 |
| 27 | Gomisin F | −0.5 | 69.25 | 515.2203 [M+H]+ | 469.2176, 438.2017, 385.1638, 355.1537, 315.0859 |
| 28 | Schisantherin C | −0.5 | 70.17 | 515.2203 [M+H]+ | 469.2222, 438.1801, 385.1635, 355.1531, 316.0940 |
| 29 | Gomisin G | 0.0 | 71.18 | 537.2046 [M+H]+ | 491.2034, 475.2089, 407.1452, 316.0940, 302.0772 |
| 30 | Schisandrin A | −0.9 | 77.81 | 417.2199 [M+H]+ | 417.2251, 402.2034, 386.2088, 316.1291, 301.1059 |
| 31 | Gomisin N | −0.5 | 80.27 | 401.1886 [M+H]+ | 386.1718, 370.1772, 300.4007, 285.0755, 242.0929 |
| 32 | Schisandrin B | −0.4 | 80.36 | 401.1886 [M+H]+ | 386.1718, 370.1772, 300.4007, 285.0755, 242.0929 |
| 33 | BenzoylisogomisinO | −0.9 | 84.84 | 521.2097 [M+H]+ | 543.1984, 421.1605, 399.1779, 369.1692, 315.0846 |
| 34 | Schisandrin C | −0.1 | 85.09 | 385.1573 [M+H]+ | 385.1636, 355.1532, 338.1132, 315.0857, 299.0876 |
| 35 | Schisanlactone E | −0.5 | 85.60 | 469.3242 [M+H]+ | 451.3176, 433.3098, 423.3237, 337.2525, 311.2370 |
| 36 | Mexicanolide | −0.8 | 86.61 | 469.2148 [M+H]+ | 491.2019, 476.0341, 435.3217, 387.1814, 339.1210 |
| 37 | Lancifodilactone C | 0.9 | 14.64 | 545.2386 [M+H]+ | 527.2292, 485.2170, 467,2073, 439.2131, 403.1909 |
| 38 | Schisanlactone B | 1.5 | 15.52 | 501.2119 [M+H]+ | 487.2031, 425.1936, 345.1683, 379.1521, 288.0826 |
| 39 | Schisanwilsonin A | 2.8 | 16.94 | 523.1914 [M+Na]+ | 469.1657, 425.1433, 353.0876, 337.1054, 311.0901 |
| 40 | Schindilactone A | 0.7 | 20.30 | 543.2152 [M+H]+ | 563.2048, 503.1967, 463.1752, 437.2334, 407.1871 |
| 41 | Gomisin S | 2.9 | 30.27 | 419.2077 [M+H]+ | 402.2005, 369.1720, 337.1448, 323.1274, 301.1042 |
| 42 | Pregomisin | −0.3 | 38.36 | 413.1934 [M+Na]+ | 391.1702, 359.1829, 351.1555, 327.1581, 299.1555 |
| 43 | Kadsuphilactone B | 0.7 | 51.14 | 505.2924 [M+H]+ | 483.3090, 464.2474, 438.6657, 425.1936, 345.1663 |
| 44 | Propindilactone G | −0.2 | 69.49 | 514.2566 [M+H]+ | 479.4076, 400.1871, 384.1931, 369.1698, 338.1511 |
| 45 | Schisanlactone D | −2.5 | 91.21 | 453.3325 [M+H]+ | 435.3240, 313.2222, 270.1898, 245.1885, 111.1018 |
Identified in plasma samples.
Identified in both plasma and brain samples.
Figure 4TCC of (A) plasma and (B) brain samples in positive ion mode.
Figure 5Peak areas of lignans corrected by Bifendate in vitro. For statistical significance, *P < 0.05, **P < 0.01.
Figure 6Peak areas of lignans corrected by Bifendate in vivo. (A) Contents in plasma samples. (B) Contents in brain samples. For statistical significance, *P < 0.05, **P < 0.01.
Figure 7Pathways of all active chemical compositions based on bioinformation analysis.
Figure 8The enrichment degree of target pathways on function groups. Corresponding functional groups related to schisandrol A, gomisin J, schisandrin A, schisandrin B and gomisin N respected with relevant color, respectively.
The ratio of Aanalytes/AIS of EES and WES in vitro/in vivo.
| Lignan | Ratio (E/W) | Plasma ( | Ratio (E/W) | Brain ( | Ratio (E/W) | ||||
|---|---|---|---|---|---|---|---|---|---|
| WES | EES | WES | EES | WES | EES | ||||
| 6 | 1.84±0.58 | 2.19±0.27 | 1.19 | 0.84±0.01 | 1.76±0.54 | 2.08* | – | – | – |
| 7 | 92.07±18.61 | 190.60±6.71 | 2.07** | 1.02±0.38 | 9.88±2.13 | 9.67** | 0.64±0.30 | 0.41±0.36 | 0.64 |
| 9 | 6.13±0.59 | 15.32±0.37 | 2.50** | 0.41±0.35 | 0.54±0.20 | 1.32 | – | – | – |
| 11 | 6.17±0.26 | 44.75±6.62 | 7.25** | 4.42±1.37 | 3.02±1.54 | 0.68 | 3.98±2.30 | 4.10±1.30 | 1.03 |
| 12 | 5.79±0.59 | 16.72±1.68 | 2.89* | 0.02±0.01 | 0.41±0.12 | 20.50** | – | – | – |
| 13 | 5.69±0.67 | 16.07±1.48 | 2.83* | 0.02±0.01 | 0.38±0.18 | 19.06** | – | – | – |
| 14 | 6.03±0.81 | 17.17±2.06 | 2.85* | 0.12±0.05 | 0.52±0.20 | 4.33* | – | – | – |
| 16 | 5.53±0.61 | 17.07±1.62 | 3.09** | 1.13±0.53 | 1.29±0.28 | 1.14 | – | – | – |
| 21 | 17.53±7.12 | 87.62±14.15 | 5.00** | 7.79±2.68 | 8.62±1.33 | 1.11 | – | – | – |
| 22 | 20.03±7.48 | 85.12±11.97 | 4.25* | 9.19±4.56 | 7.82±3.31 | 0.85 | – | – | – |
| 29 | 1.71±0.79 | 52.19±20.88 | 30.58** | 16.92±3.48 | 46.23±18.76 | 2.73* | – | – | – |
| 30 | 6.45±0.75 | 364.49±10.98 | 56.52** | 5.04±0.84 | 13.06±2.97 | 2.60** | 5.53±3.74 | 6.07±3.54 | 1.10 |
| 31 | 22.73±8.63 | 308.96±2.78 | 13.59** | 6.47±2.28 | 19.13±4.94 | 2.96* | 4.54±3.77 | 3.62±2.11 | 0.80 |
| 32 | 20.79±3.48 | 181.85±9.68 | 8.75** | 3.19±1.09 | 12.47±2.87 | 3.91** | 13.99±5.78 | 12.74±3.13 | 0.91 |
| 34 | 0.56±0.12 | 37.11±0.96 | 66.22** | 0.48±0.23 | 2.83±2.73 | 11.63** | – | – | – |
For statistical significance, *P < 0.05, **P < 0.01. –Not applicable.